TERTp mutations are common in gliomas, occurring in around 40% of Grade II and III gliomas, 40% of IDH‐mutant (IDH‐mt) gliomas, and 70% of IDH‐wildtype (IDH‐wt) gliomas [11, 12, 13, 14]. Here, IDH2 is linked to central nervous system cancer.